Dravet Syndrome, Lennox Gastaut Syndrome, Tuberous Sclerosis Complex
Conditions
Keywords
Liver injury, Liver fibrosis, Epidiolex, Cannabidiol
Brief summary
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
Interventions
DRUGCannabidiol
Oral Cannabidiol solution 100 mg/mL
Sponsors
Jazz Pharmaceuticals
Jazz Pharmaceuticals Research UK Limited
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant is within the approved age range as per labeling recommendations. Participants aged 1 to 3 years who are in the FibroScan subset will not undergo FibroScan assessments until they reach 4 years of age. * Participant is either on existing Epidiolex therapy for treatment of a seizure disorder or is to be started on Epidiolex for treatment of an Food and Drug Administration (FDA)-approved indication. * Participant is willing to refrain from strenuous exercise 48 to 72 hours prior to all study visits with the exception of unscheduled visits. * Any non-pharmacological therapies (e.g., ketogenic diet) must also be stable up to 4 weeks prior to Screening Visit and expected to be stable throughout the duration of the study.
Exclusion criteria
* Participant is currently using or within 3 months of screening has used recreational or medicinal cannabis, or synthetic cannabinoid-based medications, not including Epidiolex if currently prescribed. * Participant is not planning to abstain from using recreational cannabinoids or medicinal cannabis, or synthetic cannabinoid-based medications during the study. * Female participant is pregnant (positive pregnancy test), lactating or planning pregnancy during the course of the study and for 3 months thereafter. * Participant has any other significant disease or disorder which, in the opinion of the investigator, may either put the participant, other participants, or site staff at risk because of participation in the study, may influence the result of the study, or may affect the participant's ability to take part in the study * Participant has diseases or disorders which are associated with liver fibrosis with a FibroScan score of ≥ 6.5 Kilopascals (where FibroScan results are available). * Positive serology panel (including hepatitis B surface antigen and hepatitis C virus antibody) and/or positive human immunodeficiency virus antibody/p24 antigen screens at screening. * Following a physical examination, if the participant has any abnormalities that, in the opinion of the investigator, would prevent the participant from safe participation in the study. * Participant has significantly impaired hepatic function at Screening Visit alanine aminotransferase or aminotransferase \> 3 x upper limit of normal (ULN), and total bilirubin \> 2 x ULN or international normalized ratio \> 1.5. * Participant is planning to have epilepsy surgery or other major surgery within five years. * Participant has or plans to have any medical device implanted that is contraindicated for use with FibroScan (only applicable for FibroScan subset), with the investigator consulting with the Sponsor as needed. * Participation in any clinical trial involving an investigational medicinal product within 3 months prior to the Screening Visit or at any point during this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants With Liver Fibrosis and Evaluable Fibrotic Changes as Determined and Assessed by an Independent Adjudication Committee | Screening, Day 365, Day 730, Day 1095, Day 1460, and Day 1825 |
Secondary
| Measure | Time frame |
|---|---|
| Change From Baseline in Aspartate Aminotransferase (AST) to Platelet Ratio Index | Baseline, Day 365, Day 730, Day 1095, Day 1460, and Day 1825 |
| Change from Baseline in the Enhanced Liver Fibrosis Score | Baseline, Day 365, Day 730, Day 1095, Day 1460, and Day 1825 |
| Change From Baseline in Fibrosis-4 | Baseline, Day 365, Day 730, Day 1095, Day 1460, and Day 1825 |
| Change From Baseline in FibroScan Scoring (FibroScan subset only) | Baseline, Day 365, Day 730, Day 1095, Day 1460, and Day 1825 |
| Number of Participants With Potential Drug-Induced Liver Injury (DILI) | Day 1, Day 365, Day 730, Day 1095, Day 1460, and Day 1825 |
| Number of Participants with Severe Treatment-emergent Adverse Events (TEAEs) | Day 1, Day 365, Day 730, Day 1095, Day 1460, and Day 1825 |
| Number of Participants With Clinically Significant Clinical Laboratory Findings | Day 1, Day 365, Day 730, Day 1095, Day 1460, and Day 1825 |
| Number of Participants With Clinically Significant Physical Examinations | Day 1, Day 365, Day 730, Day 1095, Day 1460, and Day 1825 |
Countries
United States
Outcome results
None listed